[HTML][HTML] Psoriasis management challenges regarding difficult-to-treat areas: therapeutic decision and effectiveness
AC Nicolescu, MA Ionescu, MM Constantin, I Ancuta… - Life, 2022 - mdpi.com
Psoriasis is not optimally controlled in spite of newly developed treatments, possibly due to
the difficulty of objectively quantifying the disease's severity, considering the limitations of …
the difficulty of objectively quantifying the disease's severity, considering the limitations of …
Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial
K Reich, AW Armstrong, RG Langley, S Flavin… - The Lancet, 2019 - thelancet.com
Background Antibodies targeting interleukin (IL)-23 and IL-17A effectively treat moderate-to-
severe psoriasis. ECLIPSE is the first comparator study of an IL-23p19 inhibitor …
severe psoriasis. ECLIPSE is the first comparator study of an IL-23p19 inhibitor …
Guselkumab: the first selective IL-23 inhibitor for active psoriatic arthritis in adults
WH Boehncke, NC Brembilla… - Expert review of clinical …, 2021 - Taylor & Francis
Introduction Guselkumab is a subcutaneously administered human monoclonal antibody,
selectively blocking IL-23 through binding to its p19 subunit. It was initially approved for the …
selectively blocking IL-23 through binding to its p19 subunit. It was initially approved for the …
Psoriasis treat to target: defining outcomes in psoriasis using data from a real‐world, population‐based cohort study (the British Association of Dermatologists …
Background The 'treat to target'paradigm improves outcomes and reduces costs in chronic
disease management but is not yet established in psoriasis. Objectives To identify treatment …
disease management but is not yet established in psoriasis. Objectives To identify treatment …
[HTML][HTML] Treat-to-target approach for the management of patients with moderate-to-severe plaque psoriasis: consensus recommendations
Introduction Treat-to-target strategies are used in several chronic diseases to improve
outcomes. Treatment goals have also been suggested for psoriasis, but there is currently no …
outcomes. Treatment goals have also been suggested for psoriasis, but there is currently no …
[HTML][HTML] [Translated article] Practical Update of the Recommendations Published by the Psoriasis Group of the Spanish Academy of Dermatology and Venereology …
Background and objectives A new, updated AEDV Psoriasis Group (GPs) consensus
document on the treatment of moderate to severe psoriasis was needed owing to the …
document on the treatment of moderate to severe psoriasis was needed owing to the …
[HTML][HTML] Real-world effectiveness of anti-interleukin-23 antibodies in chronic plaque-type psoriasis of patients from the Austrian Psoriasis Registry (PsoRA)
T Graier, W Weger, C Jonak, P Sator, C Zikeli… - Scientific Reports, 2022 - nature.com
With the introduction of the latest class of biologic drugs targeting interleukin (IL)-23p19,
three new, highly effective drugs can be used for the treatment of chronic plaque psoriasis …
three new, highly effective drugs can be used for the treatment of chronic plaque psoriasis …
Comparison of tightly controlled dose reduction of biologics with usual care for patients with psoriasis: a randomized clinical trial
S Atalay, JMPA van den Reek… - JAMA …, 2020 - jamanetwork.com
Importance Biologics revolutionized the treatment of psoriasis. Biologics are given in a fixed
dose, but lower doses might be possible. Objective To investigate whether dose reduction …
dose, but lower doses might be possible. Objective To investigate whether dose reduction …
Effectiveness and safety of guselkumab for the treatment of psoriasis in real‐world settings at 24 weeks: a retrospective, observational, multicentre study by the …
E Del Alcázar, A López‐Ferrer… - Dermatologic …, 2022 - Wiley Online Library
Data on the effectiveness and safety of a drug in real‐world clinical practice complement the
evidence from clinical trials, which are carried out in a different setting. Little has been …
evidence from clinical trials, which are carried out in a different setting. Little has been …
Absolute and relative psoriasis area and severity index (PASI) treatment goals and their association with health-related quality of life
S Gerdes, A Körber, M Biermann… - Journal of …, 2020 - Taylor & Francis
Abstract Background: Relative Psoriasis Area and Severity Index (PASI) improvement, also
called 'PASI response', is recommended in major guidelines for assessment of treatment …
called 'PASI response', is recommended in major guidelines for assessment of treatment …